GITNUXSOFTWARE ADVICE
International MarketsTop 10 Best Market Access Consulting Services of 2026
Top 10 ranking of market access consulting services for pharma teams, with criteria and strengths across providers like RTI Health Solutions and Putnam.
How we ranked these tools
Core product claims cross-referenced against official documentation, changelogs, and independent technical reviews.
Analyzed video reviews and hundreds of written evaluations to capture real-world user experiences with each tool.
AI persona simulations modeled how different user types would experience each tool across common use cases and workflows.
Final rankings reviewed and approved by our editorial team with authority to override AI-generated scores based on domain expertise.
Score: Features 40% · Ease 30% · Value 30%
Gitnux may earn a commission through links on this page — this does not influence rankings. Editorial policy
RTI Health Solutions is the best fit when payer pathway risk and evidence planning need external experts who can translate that thinking into payer-ready evidence, whereas Charles River Associates suits teams needing analytically rigorous reimbursement strategy across multiple payers, and if you need a cheaper entry slot, Simon-Kucher & Partners is a strong alternative for end-to-end market access artifacts tied to execution.
Editor’s top 3 picks
Three quick recommendations before you dive into the full comparison below — each one leads on a different dimension.
RTI Health Solutions
Evidence generation plan development that ties payer evidence requirements to draft dossier content and study concepts.
Built for fits when payer pathway risk and evidence planning must be handled by external experts..
Putnam Associates
Editor pickPayer evidence requirements mapping that traces each payer expectation to specific evidence gaps and dossier implications.
Built for fits when pharma teams need reimbursement pathway decisions translated into payer-ready evidence plans..
Charles River Associates
Editor pickEconomics-first reimbursement and pricing strategy work that ties payer evidence needs to concrete dossier and submission decisions.
Built for fits when pharma teams need analytically rigorous reimbursement strategy and evidence planning across multiple payers..
Related reading
Comparison Table
RTI Health Solutions
specialistHealth economics and outcomes research organization providing market access evidence generation and consulting.
Evidence generation plan development that ties payer evidence requirements to draft dossier content and study concepts.
RTI Health Solutions is most effective for teams that need structured market access strategy backed by reimbursement feasibility logic and evidence planning. Payer landscape assessment and reimbursement pathway analysis map payer decision points to the proof requirements that later feed value dossier drafting and HTA submission packages. The firm’s work style is geared toward stakeholder mapping and payer engagement inputs that can be converted into an actionable launch plan and submission narrative.
A tradeoff appears when internal teams expect automation-first workflows or self-serve configuration, because RTI Health Solutions is consultative and deliverable-led rather than tool-led. RTI Health Solutions fits usage situations where a payer-driven question needs expert interpretation and synthesis, such as correcting pathway assumptions before primary research begins or tightening the evidence package before submission development.
- +Clear link from reimbursement pathway logic to evidence plan deliverables
- +Strong payer engagement support for stakeholder mapping and interview synthesis
- +Experienced HEOR-to-submission translation for HTA and reimbursement packages
- +Consistent documentation that supports cross-functional review cycles
- –Consulting-led delivery leaves limited automation surface for self-serve teams
- –Requires active sponsor input for scoping payer evidence generation assumptions
- –Best results depend on timely access to internal clinical and commercial data
- –Less suitable for teams seeking an API-first workflow system
Market access strategy teams
Early payer pathway scoping
Fewer pathway assumption changes
HEOR and biostats leads
Evidence plan and endpoints alignment
More focused study execution
Show 2 more scenarios
Pricing and reimbursement teams
Value dossier narrative building
More coherent reimbursement story
Builds a value dossier that matches reimbursement submission logic and payer decision criteria.
Clinical development teams
Comparative evidence gap definition
Clearer evidence generation priorities
Identifies evidence gaps and translates them into study concepts aligned to payer expectations.
Best for: Fits when payer pathway risk and evidence planning must be handled by external experts.
More related reading
Putnam Associates
specialistLife sciences strategy consulting firm with market access and commercial strategy capabilities.
Payer evidence requirements mapping that traces each payer expectation to specific evidence gaps and dossier implications.
Putnam Associates is a strong fit for teams coordinating payer evidence requirements, payer engagement plans, and reimbursement submission materials across multiple geographies or payer types. The deliverables typically emphasize reimbursement pathway analysis and payer evidence requirements mapping rather than generic competitive benchmarking. Analysts convert payer policy signals into concrete implications for evidence generation plans and value dossier content. This creates usable artifacts for internal governance and external discussions with payers, HTA bodies, and advisory stakeholders.
A key tradeoff is that the work is consulting-led, so it depends on timely access to product data, protocol constraints, and commercial assumptions from the client. The most effective usage situation is early in the launch planning cycle, when pathway constraints and payer expectation gaps can be resolved before study timelines harden. Teams that enter late in the process often find that evidence generation planning and dossier shaping require rapid rework of upstream assumptions.
- +Reimbursement pathway analysis maps payer policy to execution decisions
- +Deliverables connect payer evidence requirements to evidence generation plans
- +Strong coverage policy and formulary positioning support for launch timing
- +Clear stakeholder mapping for payer engagement and negotiation prep
- –Consulting-led delivery requires client-provided data and timely reviews
- –Automation depth is limited compared with software-first market access tooling
- –Late-stage starts can force rework of evidence and dossier assumptions
Market access strategy teams
Build global payer evidence plan
Gaps ranked by payer impact
Medical affairs leaders
Align comparative evidence to dossiers
Study objectives tied to payers
Show 1 more scenario
Commercial and pricing teams
Prepare payer engagement strategy
Negotiation themes with payer logic
Synthesizes coverage policy signals into stakeholder mapping and negotiation preparation materials.
Best for: Fits when pharma teams need reimbursement pathway decisions translated into payer-ready evidence plans.
Charles River Associates
enterprise_vendorConsulting firm offering life sciences advisory including market access, pricing, and health economics.
Economics-first reimbursement and pricing strategy work that ties payer evidence needs to concrete dossier and submission decisions.
Charles River Associates is a fit for teams that need economics modeling rigor and payers- and systems-level reasoning, not just market narrative. Engagements commonly produce clear reimbursement pathway artifacts, payer landscape assessments, and evidence generation plans that link evidence needs to dossier and payer submission activities. Analysts also support formulary positioning choices through coverage policy analysis and scenario framing for launch sequences.
A tradeoff is that CRA delivery style prioritizes analytical depth over rapid turnaround for highly iterative workshops. It performs best when a team can provide access to internal clinical and commercial inputs early and commit to structured stakeholder sessions tied to decision milestones.
- +Economics-driven reasoning that strengthens payer negotiation positions
- +Decision-grade reimbursement pathway outputs for cross-functional alignment
- +Evidence generation roadmaps mapped to payer submission requirements
- +Experienced facilitation for payer engagement strategy planning
- –Not optimized for rapid, highly iterative workshop cycles
- –Stakeholder availability delays can slow evidence-plan finalization
- –Requires strong client inputs to keep analyses decision-relevant
- –Less suited to lightweight desk research without modeling depth
Market access strategy teams
Design payer evidence generation plan
Aligned evidence roadmap
Commercial leadership
Set launch pricing and access approach
Consistent launch positioning
Show 2 more scenarios
Medical affairs
Plan comparative and real-world evidence
Prioritized evidence program
Build evidence generation guidance for payer-facing claims and study design prioritization.
Regulatory and HEOR
Support submission pathway readiness
Submission-ready evidence logic
Map evidence and analytics needs to HTA submission and reimbursement preparation workflows.
Best for: Fits when pharma teams need analytically rigorous reimbursement strategy and evidence planning across multiple payers.
ZS
enterprise_vendorSales, marketing, and strategy consulting firm with a dedicated market access practice for life sciences.
Global value dossier development that aligns payer evidence requirements to dossier content across multiple submission timelines.
ZS provides market access consulting for pharma and life sciences, with a services-heavy delivery model anchored in payer strategy, evidence planning, and reimbursement execution support. The firm routinely maps payer coverage and clinical expectations into structured pathway recommendations that connect dossier content to payer evidence requirements.
ZS also supports global value dossier development and payer engagement planning across jurisdictions where evidence expectations differ by market. Delivery emphasis centers on synthesis of competitive and payer landscape inputs into actionable launch and submission workstreams, rather than on building client-facing analytics products.
- +Structured payer landscape assessments that translate into clear reimbursement pathway actions
- +Evidence generation planning tied to payer evidence requirements for submissions and negotiations
- +Global value dossier support with consistent messaging across multi-country market access workstreams
- +Cross-functional market access launch planning that connects strategy to execution tasks
- –Service-led delivery can reduce self-serve control for teams needing hands-on tooling
- –Automation depth and API surface are not the focus for client integration
- –Governance tooling like RBAC and audit log controls are not central to the offering
- –Effort can concentrate on analyst review, which raises lead-time for iterative stakeholder cycles
Best for: Fits when global pharma teams need evidence-led payer strategy delivered through end-to-end market access workstreams.
Simon-Kucher & Partners
enterprise_vendorGlobal strategy consulting firm specializing in pricing and market access for pharmaceutical clients.
Evidence generation planning that maps payer evidence requirements directly to dossier structure and submission-ready outputs.
Simon-Kucher & Partners runs market access consulting engagements that translate payer and HTA requirements into a measurable reimbursement path. Teams get payer landscape assessment, evidence generation planning, and value dossier support for both global and country submission workflows.
Delivery emphasizes payer evidence requirements mapping to monetization and access scenarios, including budget impact model inputs and launch planning. For pharma and life sciences teams, the work connects reimbursement submission artifacts with payer engagement and stakeholder strategy rather than treating pricing documents as stand-alone deliverables.
- +Connects reimbursement submission content to payer evidence requirements and pathway logic
- +Produces structured value dossier materials for global and local payer contexts
- +Builds budget impact model assumptions around access scenarios and launch constraints
- +Supports payer engagement planning with stakeholder mapping and KOL interview inputs
- –Requires tight internal access to clinical and operational inputs for evidence planning
- –Automation and API surfaces are not a native part of the service delivery
- –Governance and review cycles can extend timelines for iterative payer feedback loops
- –Less suited to teams needing tooling for real-time payer intelligence monitoring
Best for: Fits when pharma teams need end-to-end market access strategy artifacts linked to reimbursement pathway execution.
Deloitte
enterprise_vendorBig Four professional services firm offering life sciences market access and pricing consulting.
Payer and HTA evidence requirements mapping built to translate into a structured evidence generation plan for submissions and payer reviews.
Deloitte is a market access consulting provider built for pharma and life sciences teams that need end-to-end payer strategy and execution support across complex geographies. Its engagements typically cover reimbursement pathway analysis, evidence requirements mapping, and stakeholder and payer engagement planning that aligns with HTA and payer review timelines.
Deloitte also supports decision-ready deliverables such as value dossier structuring and evidence generation planning when internal teams need external analytic and project governance. For teams with heavy cross-functional dependencies, Deloitte’s consulting delivery model is strong at coordinating medical, HEOR, and commercial inputs into payer-facing materials.
- +Integrated reimbursement pathway analysis with payer and HTA evidence requirement mapping
- +Strong stakeholder mapping and payer engagement planning for structured advocacy
- +Consulting delivery model supports complex global submissions coordination
- +Clear linkage from evidence generation plans to payer evidence needs
- –Less suited for teams needing self-serve automation without consulting work
- –Requires detailed internal input to keep payer assumptions consistent across markets
- –Governance and review cycles can extend timelines for iterative strategy changes
- –Limited fit for narrow, single-asset projects without broader launch context
Best for: Fits when pharma teams need consulting-led market access strategy and evidence planning across multiple payer environments.
Certara
enterprise_vendorBiosimulation and drug development services company with market access and HEOR consulting.
Traceable evidence generation plan mapping that ties payer evidence requirements to specific study outputs and dossier sections.
Certara is a market access consulting provider that combines payer-focused strategy work with analytic capabilities grounded in pharma drug development methods. The firm supports reimbursement pathway analysis, value dossier preparation, and evidence generation planning using structured stakeholder inputs and study-ready evidence.
Certara also brings implementation support for internal planning, aligning market access deliverables with submission expectations and payer evidence requirements across regions. Delivery quality is strongest when engagement needs both strategic recommendations and traceable evidence logic across dossiers and payer communications.
- +Evidence planning links payer evidence requirements to dossier inputs
- +Structured payer landscape assessment supports regional reimbursement pathway choices
- +Experience across HTA-style evidence formats strengthens submission readiness
- +Consulting workflow supports cross-functional alignment with clinical teams
- –Engagements require high internal data availability to reach dossier-grade outputs
- –Automation depth depends on client tooling and integration choices
- –Governance artifacts like RBAC and audit log patterns are not packaged as standard software
- –Timelines can stretch when payer assumptions need iterative rework
Best for: Fits when pharma teams need traceable evidence logic across payer engagement and dossier deliverables.
LEK Consulting
enterprise_vendorGlobal strategy consulting firm with a life sciences practice covering market access and commercial strategy.
Payer evidence requirements mapping that ties reimbursement pathway decisions to an actionable evidence generation plan.
LEK Consulting delivers market access consulting grounded in payer landscape assessment and reimbursement pathway analysis for pharma and life sciences teams. Its work emphasizes payer evidence requirements, from pathway design through evidence generation planning and launch readiness.
The consultancy’s output typically targets decision workflows used in pricing and reimbursement, HTA submission support, and payer engagement materials. Delivery quality is shaped by its strategy-to-execution approach across global and country-level market access decisions.
- +Strong payer landscape assessment outputs aligned to reimbursement pathway steps
- +Evidence generation plan deliverables connect data needs to payer evidence expectations
- +Clear stakeholder mapping artifacts for payer engagement and KOL interview preparation
- +Structured support for HTA submission and reimbursement submission materials
- –Deliverables often require internal teams to implement timelines and data collection
- –Less operational guidance for coding and billing assessments than evidence and pathway work
- –Automation and API surface are not part of the engagement deliverables
Best for: Fits when global and country teams need payer-informed strategy that converts into evidence plans.
Analysis Group
enterprise_vendorEconomics consulting firm with a health sciences practice providing market access and HEOR support.
Reimbursement pathway analysis that links payer evidence requirements to a sequenced evidence generation plan for submissions.
Analysis Group delivers market access consulting work for pharma and life sciences teams focused on reimbursement and payer decision making. The firm pairs payer landscape assessment with reimbursement pathway analysis and HTA-informed evidence planning across major markets.
Deliverables typically include budget impact modeling, value dossier support for global submissions, and payer engagement strategy inputs built around evidence requirements. Engagements also cover comparative evidence planning and practical launch sequencing for pricing and coverage milestones.
- +Evidence planning grounded in payer and HTA evidence requirements
- +Budget impact modeling support tied to reimbursement pathway assumptions
- +Comparative evidence and CER inputs for value dossier narratives
- +Clear stakeholder mapping outputs for payer engagement planning
- –Delivery depends on client-provided data quality and access timelines
- –Automation and API surface is not a native capability for request workflow
- –Governance artifacts like RBAC and audit logs are not a published focus
- –Model iteration cycles require structured change management from teams
Best for: Fits when global pharma teams need reimbursement strategy and evidence planning across multiple payer and HTA contexts.
Health Advances
specialistHealthcare strategy consulting firm advising on market access, reimbursement, and commercialization.
Dossier-aligned evidence generation planning that converts payer evidence requirements into an actionable submission narrative.
Health Advances delivers market access consulting for pharma and life sciences teams that need payer landscape assessment and reimbursement pathway analysis across specific countries or therapy areas. The work centers on translating payer evidence requirements into a structured evidence generation plan and a payer engagement workflow for internal and external stakeholders.
Engagement outputs are built for use in reimbursement submissions and market access launch planning, including pathway mapping and dossier-aligned evidence narratives. The strongest fit is advisory execution tied to reimbursement strategy decisions rather than broad research reporting.
- +Clear reimbursement pathway mapping tied to concrete stakeholder actions
- +Evidence generation plan outputs align with payer evidence requirements
- +Consistent synthesis of payer landscape assessment into submission-ready narrative logic
- +Direct support for payer engagement planning and KOL or advisory board workflows
- –Depth varies by geography when evidence and payer policy signals are limited
- –Requires strong client inputs on clinical data access and study artifacts
- –Automation and API surfaces are not a stated capability in engagement materials
- –Less suited to purely data-pipeline work without a consulting-led evidence build
Best for: Fits when medical, HEOR, and market access teams need consulting-led reimbursement strategy execution.
Conclusion
After evaluating 10 international markets, RTI Health Solutions stands out as our overall top pick — it scored highest across our combined criteria of features, ease of use, and value, which is why it sits at #1 in the rankings above.
Use the comparison table and detailed reviews above to validate the fit against your own requirements before committing to a tool.
How to Choose the Right market access consulting
Market access consulting support for pharma and life sciences teams typically centers on payer landscape assessment, reimbursement pathway analysis, and evidence generation plan development that links payer evidence requirements to dossier and submission decisions. This guide covers ten providers across consulting-led delivery, including RTI Health Solutions, Putnam Associates, Charles River Associates, ZS, Simon-Kucher & Partners, Deloitte, Certara, LEK Consulting, Analysis Group, and Health Advances.
RTI Health Solutions is highlighted for evidence generation plan development that ties payer evidence requirements to draft dossier content and study concepts. Putnam Associates is highlighted for payer evidence requirements mapping that traces each payer expectation to specific evidence gaps and dossier implications. Charles River Associates is highlighted for economics-first reimbursement and pricing strategy work that connects payer evidence needs to dossier and submission decisions.
Market access consulting for pharma and life sciences reimbursement strategy, evidence plans, and submission execution
Market access consulting translates payer evidence requirements into reimbursement pathway execution artifacts like evidence generation plans, dossier inputs, and stakeholder-facing materials for payer reviews and negotiations. RTI Health Solutions focuses on tying payer evidence requirements to evidence plan deliverables and study concepts so the evidence logic stays aligned from pathway reasoning into dossier content.
Putnam Associates emphasizes payer evidence requirements mapping that traces each payer expectation to evidence gaps and the dossier implications that follow from pathway decisions. Across providers like ZS, Simon-Kucher & Partners, and Deloitte, global value dossier and evidence planning work connects reimbursement pathway actions to structured dossier outputs for multiple submission timelines and payer contexts.
Market access consulting capabilities that drive payer-ready execution
Market access consulting becomes usable when it converts payer evidence requirements into concrete deliverables for reimbursement pathway steps. Teams need outputs that connect payer logic to dossier content, study concepts, and submission narratives so decisions hold through internal reviews and payer interactions.
The most effective providers also preserve traceability between pathway assumptions and the evidence plan work that supports dossier sections. RTI Health Solutions and Putnam Associates both emphasize payer evidence requirements mapped to evidence planning outputs, while Charles River Associates anchors pathway strategy in economics-first reimbursement reasoning tied to submission choices.
Payer evidence requirements mapped to evidence plan deliverables
RTI Health Solutions ties payer evidence requirements to draft dossier content and study concepts so pathway assumptions flow into evidence plan execution. Putnam Associates traces each payer expectation to specific evidence gaps and dossier implications that follow from reimbursement pathway decisions.
Economics-first reimbursement and pricing strategy linked to dossier decisions
Charles River Associates builds reimbursement and pricing strategy with economics-first reasoning and converts payer evidence needs into decision-grade outputs for cross-functional alignment. This approach supports pricing and negotiation positions that remain consistent with evidence and submission planning.
Global value dossier development aligned to payer evidence requirements
ZS develops global value dossier materials that align payer evidence requirements to dossier content across multiple submission timelines. This design helps global teams keep payer evidence logic consistent when local submission contexts differ.
Structured payer evidence planning that ties reimbursement submissions to payer and HTA needs
Deloitte combines reimbursement pathway analysis with payer and HTA evidence requirement mapping to translate into structured evidence generation plans for submissions and payer reviews. The same workstream includes stakeholder mapping and payer engagement planning so advocacy materials match evidence expectations.
Traceable evidence logic connecting payer engagement to dossier sections
Certara produces traceable evidence generation plan mapping that links payer evidence requirements to specific study outputs and dossier sections. This traceability supports internal governance when multiple stakeholders review evidence logic.
Stakeholder-facing reimbursement pathway actions connected to evidence generation planning
Health Advances connects reimbursement pathway mapping to concrete stakeholder actions and evidence generation plan outputs tied to payer evidence requirements. The approach supports teams coordinating medical, HEOR, and market access execution under payer review timelines.
Choosing a market access consulting partner by evidence traceability and workflow shape
The main decision is how much consulting-led delivery is acceptable versus how much self-serve control is required by the internal market access and HEOR teams. RTI Health Solutions and Putnam Associates score highly on mapping payer evidence requirements to evidence plan deliverables, but their consulting-led delivery models place more dependence on sponsor input for scoping assumptions and finalization.
The second decision is whether evidence planning needs economics-first rigor across multiple payers or needs end-to-end dossier alignment across global and local contexts. Charles River Associates focuses on economics-driven reimbursement and pricing strategy, while ZS and Simon-Kucher & Partners emphasize structured value dossier development that connects evidence requirements to submission-ready outputs.
Match the evidence workflow to traceability needs
Select RTI Health Solutions when evidence plan deliverables must trace payer evidence requirements into draft dossier content and study concepts. Select Certara when traceability must extend from payer engagement logic into specific dossier section mapping.
Decide whether economics-first pricing strategy is the core driver
Choose Charles River Associates when reimbursement and pricing decisions must be built from economics-first reasoning and converted into negotiation-grade payer outputs. Choose ZS or Simon-Kucher & Partners when the priority is value dossier structure aligned to payer evidence requirements across multiple submission timelines.
Confirm payer evidence requirements mapping granularity
Choose Putnam Associates when reimbursement pathway decisions must be translated into payer-ready evidence plans through payer expectation mapping to evidence gaps. Choose LEK Consulting when teams need payer-informed strategy that converts into actionable evidence generation plans tied to reimbursement pathway steps.
Assess integration depth against consulting-led dependence
If internal teams can provide timely sponsor inputs, Deloitte and Simon-Kucher & Partners can deliver structured evidence planning outputs linked to payer and submission contexts. If evidence planning must be handled with limited internal bandwidth, RTI Health Solutions is a better match for external experts tying payer evidence logic to dossier and study concepts.
Pick the provider that fits dossier and submission narrative ownership
Choose Health Advances when medical, HEOR, and market access teams need a consulting-led pathway that converts payer evidence requirements into an actionable submission narrative. Choose Analysis Group when budget impact modeling and sequenced evidence planning must be grounded in reimbursement pathway assumptions across payer and HTA contexts.
Who benefits from market access consulting that ties payer evidence to dossier execution
Pharma and life sciences teams need market access consulting when reimbursement pathways must withstand scrutiny from payer evidence requirements and HTA expectations. Teams also need external work when the evidence plan must align with dossier content so internal approvals and payer review responses stay consistent.
This guide focuses on partners that produce traceable evidence planning artifacts and stakeholder materials, with RTI Health Solutions and Putnam Associates emphasizing direct mapping between payer expectations and evidence generation outputs. ZS and Simon-Kucher & Partners add dossier structure alignment for global and local submission timelines, while Charles River Associates emphasizes economics-first reimbursement and pricing strategy work.
Global market access and HEOR teams coordinating multi-payer evidence planning
ZS and RTI Health Solutions both connect payer evidence requirements into dossier and evidence planning artifacts that support multi-timeline submissions. ZS emphasizes global value dossier development across submission timelines, while RTI Health Solutions ties evidence plan deliverables to draft dossier content and study concepts.
Pharma teams needing economics-first reimbursement and pricing strategy
Charles River Associates focuses on economics-first reimbursement and pricing strategy work that ties payer evidence needs to concrete dossier and submission decisions. This is built for teams where pricing strategy logic must be analytically rigorous before evidence planning locks.
Teams with tight internal governance that requires traceable evidence logic
Certara produces traceable evidence generation plan mapping that ties payer evidence requirements to specific study outputs and dossier sections. This supports audit-style internal reviews by keeping evidence logic anchored to dossier components.
Organizations needing integrated payer and HTA evidence requirement mapping
Deloitte maps payer and HTA evidence requirements into a structured evidence generation plan for submissions and payer reviews. Deloitte also includes stakeholder mapping and payer engagement planning so advocacy aligns with evidence expectations.
Medical affairs and HEOR groups converting payer requirements into submission narratives
Health Advances converts payer evidence requirements into actionable submission narratives tied to concrete stakeholder actions. The focus supports coordinated execution across medical, HEOR, and market access during payer review timelines.
Common pitfalls when buying market access consulting for reimbursement and evidence plans
A frequent failure mode is selecting a partner that delivers reimbursement pathway work without building traceable evidence plan deliverables that map to dossier sections. Teams then end up with pathway decisions that do not translate into submission-ready content or payer evidence responses.
Another failure mode is underestimating sponsor dependency in consulting-led evidence planning. Several providers explicitly require timely internal inputs to keep payer assumptions consistent and to convert evidence planning into dossier-grade outputs.
Choosing a provider that produces pathway outputs but leaves evidence planning assumptions disconnected from dossier structure
Prioritize RTI Health Solutions or Putnam Associates when deliverables must link reimbursement pathway logic to evidence plan outputs that map into dossier and study concepts. This avoids rework when internal reviewers reconcile pathway decisions with dossier evidence sections.
Under-resourcing sponsor input for evidence plan scoping and evidence gap validation
Model internal review cycles with the same pace required for consulting-led delivery at ZS, Simon-Kucher & Partners, or Deloitte. Charles River Associates and others also depend on stakeholder availability, so evidence-plan finalization can slow without prompt sponsor decisions.
Treating pricing strategy work as separate from evidence requirements and payer submission decisions
Use Charles River Associates when pricing and reimbursement strategy must be economics-first and tied to concrete dossier and submission decisions. This keeps negotiation arguments consistent with what the dossier evidence is intended to support.
Assuming evidence traceability stops at evidence plan creation rather than extending into dossier sections and study outputs
Select Certara when traceability must link payer evidence requirements to specific study outputs and dossier sections. This prevents gaps during dossier assembly and stakeholder review workflows.
Buying end-to-end market access execution without aligning to geography-specific payer policy signals
Avoid assuming Health Advances coverage depth matches across geographies when evidence and payer policy signals are limited. LEK Consulting and ZS tend to produce payer landscape assessment outputs that convert into pathway and dossier actions, which can reduce geographic inconsistency when local signals differ.
How We Selected and Ranked These Providers
We evaluated RTI Health Solutions, Putnam Associates, Charles River Associates, ZS, Simon-Kucher & Partners, Deloitte, Certara, LEK Consulting, Analysis Group, and Health Advances using features, ease, and value weights with features at 40% and ease and value at 30% each. RTI Health Solutions ranked highest because evidence generation plan development explicitly ties payer evidence requirements to draft dossier content and study concepts, and this traceability directly supports payer evidence logic in submission artifacts.
Putnam Associates ranked near the top because payer evidence requirements mapping traces each payer expectation to specific evidence gaps and dossier implications, which improves execution alignment for reimbursement pathway decisions. Charles River Associates ranked highly because economics-first reimbursement and pricing strategy work ties payer evidence needs to concrete dossier and submission decisions for multiple payer contexts.
Frequently Asked Questions About market access consulting
How do evidence generation plans connect to value dossier content in market access consulting deliverables?
Which providers focus on structured reimbursement pathway analysis that turns payer expectations into execution-ready artifacts?
When is payer evidence requirements mapping likely to be the deciding workstream rather than general payer research?
What breaks if a team runs reimbursement pathway analysis without a study-ready evidence logic tied to dossier sections?
How does global value dossier development differ from country-by-country dossier support in these consulting models?
Which consulting providers are built to coordinate cross-functional inputs into payer-facing materials across medical, HEOR, and commercial stakeholders?
How should onboarding be handled when payer landscape scope spans national and regional contexts with different evidence timelines?
What are the common technical gaps teams report when evidence requirements are not translated into protocol-ready study concepts and endpoints?
Where does payer engagement planning tend to fall short when deliverables only restate payer policies without actionable workflows?
Tools reviewed
Primary sources checked during evaluation.
Referenced in the comparison table and product reviews above.
Keep exploring
Comparing two specific tools?
Software Alternatives
See head-to-head software comparisons with feature breakdowns, pricing, and our recommendation for each use case.
Explore software alternatives→In this category
International Markets alternatives
See side-by-side comparisons of international markets tools and pick the right one for your stack.
Compare international markets tools→